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Correspondence Frequency and Practice-Level Variation in
Inappropriate and Nonrecommended
Prasugrel Prescribing
Insights From the NCDR PINNACLE RegistryTo the Editor: Prasugrel signiﬁcantly decreased cardiovascular
death, myocardial infarction (MI), and stroke compared with clo-
pidogrel in TRITON-TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibition with
PrasugreldThrombolysis in Myocardial Infarction 38) (1). How-
ever, prasugrel use was associated with increased bleeding in pa-
tients with a history of previous stroke or transient ischemic attack
(TIA) and was not associated with beneﬁt in those 75 years of
age. The prasugrel package insert (2) includes a black box warning for
patients with previous stroke/TIA and also recommends against its
use in patients aged 75 years due to an increased risk of fatal
intracranial bleeding and uncertain beneﬁt, except in high-risk
situations (age 75 years with history of diabetes or a previous
MI). The current American College of Cardiology Foundation/
American Heart Association guidelines for patients with ST-
segment elevation myocardial infarction and unstable angina/
non–ST-segment elevation myocardial infarction (3,4) assign a
Class I recommendation for prasugrel use at the time of percuta-
neous coronary intervention (PCI) and a Class III (harm) recom-
mendation for its use in patients with history of TIA or stroke.
In the present study, we examined the frequency and practice-
level variation in inappropriate and nonrecommended prasugrel
prescribing in a national registry. PINNACLE is a national, pro-
spective, quality improvement registry. Site participation is volun-
tary, with data collected at the point of care for all outpatients with
coronary artery disease, heart failure, atrial ﬁbrillation, and hyper-
tension. Periodic edit checks are conducted on all records before
submission to the Centers for Medicare & Medicaid Services. We
evaluated patients receiving prasugrel from 123 practices between
July 1, 2009 (after U.S. Food and Drug Administration approval),
and June 13, 2013. Prasugrel use in patients with a documented
history of previous stroke or TIA was deﬁned as inappropriate.
Nonrecommended treatment was deﬁned as prasugrel use in
patients 75 years of age without diabetes or a previous MI.
To evaluate the frequency of inappropriate or nonrecommended
prasugrel prescribing, we used the number of patients receiving
inappropriate (or nonrecommended) prasugrel as the numerator
and all patients receiving prasugrel as the denominator in our as-
sessments. We further examined the extent of practice-level vari-
ation in inappropriate or nonrecommended prasugrel prescribing
by constructing multivariable hierarchical regression models to
determine the median rate ratio (MRR), which quantiﬁes the
likelihood that 2 randomly chosen practices would differ in treating
“identical” patients. Covariates in our model were: sex, provider type
(physician versus nurse practitioner), hypertension, dyslipidemia,
atrial ﬁbrillation, unstable angina, heart failure, and tobacco use. Wealso examined prasugrel use in patients receiving concomitant
aspirin and warfarin because the efﬁcacy and safety of prasugrel
(as a third agent) has not been evaluated in this subgroup.
We identiﬁed 27,533 patients receiving prasugrel; 3,824 patients
(13.9%) had an inappropriate indication and 1,210 patients (4.4%)
had a nonrecommended indication. When comparing patients
receiving prasugrel for an inappropriate indication versus those
receiving it appropriately, there were no differences in age or sex.
Patients in the appropriate indication group had higher rates of
private insurance and treatment by a physician provider; patients
in the inappropriate indication group had a higher prevalence of
comorbidities such as diabetes, hypertension, dyslipidemia, atrial
ﬁbrillation, heart failure, peripheral artery disease, and coronary
arterial bypass graft surgery.
The percentage of patients in individual practices receiving
prasugrel inappropriately ranged from 0% to 90% (median: 4.4%
[interquartile range: 2% to 10%]). MRR was 2.89 (95% conﬁdence
interval: 2.75 to 3.03), indicating signiﬁcant practice-level variation
(Fig. 1). This ﬁnding suggests that between 2 “identical” patients
treated at 2 randomly chosen practices, 1 patient was 189% more
likely to receive prasugrel inappropriately. Nonrecommended pra-
sugrel prescribing ranged from 0% to 19.8% (median: 2.6%
[interquartile range: 1.5% to 4.1%]); the MRR was 2.29 (95%
conﬁdence interval: 2.05 to 2.51). A total of 4,248 (15.4%) patients
received triple therapy with aspirin, warfarin, and prasugrel. Among
them, 319 received prasugrel inappropriately and 677 received
prasugrel for a nonrecommended indication.
In our study, 18.3% of patients were receiving prasugrel for an
inappropriate or a nonrecommended indication. A previous study
from Michigan found that among patients receiving prasugrel, 6%
to 10% had 1 contraindication to prasugrel (5). They reported
higher rates of bleeding and vascular complications in these patients,
with no difference in ischemic outcomes. Our analyses indicate a
higher rate of inappropriate prasugrel prescribing from a nationally
representative cohort, with signiﬁcant practice-level variation in both
inappropriate and nonrecommended prasugrel prescribing. In addi-
tion, 15.4% of patients were receiving concomitant aspirin and
warfarin with prasugrel. It is possible that triple therapy with prasu-
grel in this group, even when appropriate, may lead to increased rates
of major bleeding and offset any anti-ischemic beneﬁt of prasugrel.
Our study has several limitations. Previous TIA/stroke and
prasugrel use were self-reported. Prasugrel use without prior acute
coronary syndromes or PCI should be considered off-label; how-
ever, this information could not be reliably extracted because data
about MI and PCI were available for only 12 months prior to a
patient’s visit. Practices participating in PINNACLE may be
Figure 1
Practice-Level Variation in Inappropriate Prasugrel
Prescribing
Percentage of patients in individual practices receiving prasugrel inappropriately
ranged from 0% to 90% (median: 4.4% [interquartile range: 2% to 10%]).
The median rate ratio was 2.89 (95% conﬁdence interval: 2.75 to 3.03), indicating
signiﬁcant practice-level variation.
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2877motivated for quality improvement and, therefore, inappropriate
and nonrecommended rates may be higher in nonparticipating
practices. Data on the contraindications to clopidogrel, reason for
choosing prasugrel instead of clopidogrel, dosage of prasugrel
pertaining to patients weighing <60 kg, results of platelet function
studies, and ischemic and bleeding outcomes are not collected
in the PINNACLE registry, and analyses pertaining to these
variables, therefore, could not be performed.
Almost 1 in 5 patients receiving prasugrel had an inappropriate
or nonrecommended indication with signiﬁcant practice-level vari-
ation. Our ﬁndings suggest opportunities to improve evidence-based
prasugrel prescribing.*Ravi S. Hira, MDy
Kevin Kennedy, MSz
Hani Jneid, MDxy
Mahboob Alam, MDy
Sukhdeep S. Basra, MD, MPHy
Laura A. Petersen, MD, MPHxk{
Christie M. Ballantyne, MDy
Vijay Nambi, MD, PhDxy
Paul S. Chan, MD, MScz
Salim S. Virani, MD, PhDxyk
*Baylor College of Medicine
6620 Main Street, Suite 11D
Houston, Texas 77030
E-mail: hira@bcm.edu
http://dx.doi.org/10.1016/j.jacc.2014.04.011
From the ySection of Cardiology, Department of Medicine, Baylor
College of Medicine, Houston, Texas; zMid America Heart
Institute, Saint Luke’s Hospital, Kansas City, Missouri; xMichael
E. DeBakey VA Medical Center, Houston, Texas; kHealth Policy,Quality and Informatics Program, Michael E. DeBakey Veteran
Affairs Medical Center Health Services Research and Development
Center for Innovations, Houston, Texas; and the {Section of Health
Services Research, Department of Medicine, Baylor College of
Medicine, Houston, Texas.
Please note: Dr. Alam has been a member of the advisory board for AstraZeneca. Dr.
Petersen has received grant/research support from the National Institutes of Health
(R01 HL0791731) and the Houston VA HSR&D Center of Excellence (HFP9O-
020). Dr. Ballantyne has received grant/research support (all signiﬁcant [>$10,000]
and all paid to institution, not individual) from Abbott, Amarin, Amgen, Eli Lilly,
GlaxoSmithKline, Genentech, Merck, Novartis, Pﬁzer, Regeneron, Roche, Sanoﬁ-
Synthelabo, the National Institutes of Health, and the American Heart Association;
she has also served as a consultant for Abbott, Aegerion, Amarin, Amgen, Arena,
Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck, Novartis, Pﬁzer, Resverlogix,
Regeneron, Roche, and Sanoﬁ-Synthelabo; and on the speakers’ bureau for Abbott.
Dr. Nambi was a national monitor for a study sponsored by Anthera Inc.; a co-
investigator on a provisional patent ﬁled by Baylor College of Medicine, Roche
Diagnostics, on the use of biomarkers in heart failure prediction; and involved in a
research collaboration with GE and Tomtec. Dr. Virani has received grant/research
support in the form of a Department of Veterans Affairs Health Services Research
and Development Career Development Award (09-028) and an American Diabetes
Association Clinical Science and Epidemiology Award (1-14-CE-44). All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose. The views expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.REFERENCES
1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi-
dogrel in patients with acute coronary syndromes. N Engl J Med 2007;
357:2001–15.
2. Prasugrel [package insert]. Indianapolis, IN: Eli Lilly and Company,
2013.
3. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction: a
report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. Circulation 2013;
127:e362–425.
4. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused
update of the guideline for the management of patients with unstable
angina/non-ST-elevation myocardial infarction (updating the 2007
guideline and replacing the 2011 focused update): a report of the
American College of Cardiology Foundation/American Heart Associa-
tion Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:
645–81.
5. Sandhu A, Seth M, Dixon S, et al. Contemporary use of prasugrel in
clinical practice: insights from the Blue Cross Blue Shield of Michigan
Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes 2013;6:
293–8.Placebo in Autologous
Cell-Based Interventions
Hard Pill to Swallow?To the Editor: Cell-based strategies are under intense investiga-
tion in the pursuit to develop new effective treatment protocols
for ischemic heart disease (IHD). These strategies have been
mainly based on the use of tissue-speciﬁc autologous stem/
progenitor cells such as cells from bone marrow, adipose tissue,
or the heart itself (1). Several of these cell types have reached the
